2015
DOI: 10.1016/j.vaccine.2015.05.007
|View full text |Cite
|
Sign up to set email alerts
|

Construction and evaluation of DNA vaccine encoding Hantavirus glycoprotein N-terminal fused with lysosome-associated membrane protein

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
19
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
8
2

Relationship

3
7

Authors

Journals

citations
Cited by 26 publications
(19 citation statements)
references
References 46 publications
(47 reference statements)
0
19
0
Order By: Relevance
“…The improved plaque formation test is dependent on the low pH-induced cytopathic effects of hantavirus but is time-consuming and has low reproducibility. The most widely adopted approach to test hantavirus titers (especially for HTNV) is the TCID50 (50% tissue culture infective dose) calculation using ELISA as previously reported by our group (Xu et al, 2002; Cheng et al, 2014; Jiang et al, 2015; Ye et al, 2015a,b; Ying et al, 2016); however, virus propagation in Vero E6 cells takes at least 10 days. All the reported detective measurements have insurmountably objective drawbacks, such as high demanding experimental conditions for qRT-PCR and expensive apparatus and labware for FCM, which limits their applicability (Wan et al, 2010).…”
Section: Introductionmentioning
confidence: 99%
“…The improved plaque formation test is dependent on the low pH-induced cytopathic effects of hantavirus but is time-consuming and has low reproducibility. The most widely adopted approach to test hantavirus titers (especially for HTNV) is the TCID50 (50% tissue culture infective dose) calculation using ELISA as previously reported by our group (Xu et al, 2002; Cheng et al, 2014; Jiang et al, 2015; Ye et al, 2015a,b; Ying et al, 2016); however, virus propagation in Vero E6 cells takes at least 10 days. All the reported detective measurements have insurmountably objective drawbacks, such as high demanding experimental conditions for qRT-PCR and expensive apparatus and labware for FCM, which limits their applicability (Wan et al, 2010).…”
Section: Introductionmentioning
confidence: 99%
“…15 A candidate ANDV vaccine is likely to be available for use in human trials in the near future. [16][17][18][19] A Hantaan virus (HTNV) inactivated vaccine has been in use in China since 1990. DNA vaccines carrying plasmids with M segments from pathogenic New and Old World hantaviruses are in development.…”
Section: Introductionmentioning
confidence: 99%
“…However, these inactivated vaccines have many shortcomings, including poor immunogenicity, which hinders the production of neutralizing antibodies or cell-mediated immunity (Song et al, 1992), and the concern of safety when using inactivated vaccines, which may contain some infectious particles. Furthermore, there is no study reporting that it could establish long-term memory immunity (Jiang et al, 2015). Thus, it is necessary to develop an alternative immunotherapy strategy that can induce robust humoral immune response to produce therapeutically effective antiviral antibodies and T cell-mediated autoimmune responses.…”
Section: Introductionmentioning
confidence: 99%